Skip to content

Veracyte VCYT Ratios & Valuation

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
Profitability
Gross margin70.9%+0.8pp70.1%+1.6pp68.5%+0.3pp68.3%+0.2pp68%+1.1pp
Operating margin14.3%+3.1pp11.2%+6.2pp5%+2.1pp2.9%-2.2pp5.1%+1.5pp
Net margin16.2%+3.4pp12.8%+6.7pp6.1%+0.6pp5.5%-1.6pp7.1%+1.7pp
EBITDA margin18.3%+3.0pp15.3%+5.8pp9.5%+1.8pp7.7%-2.4pp10.1%+1.2pp
Free cash flow margin28.7%+4.2pp24.5%+4.7pp19.8%+2.3pp17.5%+0.6pp16.9%+2.6pp
Returns
Return on equity6.9%+1.6pp5.3%+2.8pp2.5%+0.3pp2.2%-0.6pp2.9%+0.7pp
Return on assets6.4%+1.5pp4.9%+2.6pp2.3%+0.3pp2%-0.6pp2.6%+0.6pp
Return on invested capital7.1%+1.3pp5.9%+3.3pp2.6%+1.2pp1.4%-1.0pp2.4%+0.6pp
Efficiency
Asset turnover0.4×0.0×0.4×0.0×0.4×0.0×0.4×0.0×0.4×0.0×
Liquidity
Current ratio9.3×+1.2×8.1×+1.9×6.2×+0.8×5.4×+0.3×5.1×+0.4×
Quick ratio9.3×+1.5×7.8×+1.9×5.9×+0.8×5.1×+0.3×4.8×+0.3×
Cash ratio4.7×-1.4×6.1×+1.7×4.4×+1.5×2.9×+0.4×2.5×-0.6×
Leverage
Debt-to-equity0.0×0.0×0.0×0.0×0.0×
Debt-to-assets0.0×0.0×0.0×0.0×0.0×
Net debt / EBITDA-2.3×+1.8×-4.1×+1.8×-5.9×-1.2×-4.6×-1.7×-2.9×+1.9×
Per Share
Book value per share$16.53+1.7%$16.25+3.0%$15.78+1.3%$15.58+4.4%$14.93-0.8%
Valuation
Market capitalization$2.56B-23.1%$3.33B+23.2%$2.7B+28.3%$2.11B-8.9%$2.31B-24.7%
Enterprise value$2.33B-22.3%$3B+23.9%$2.42B+25.3%$1.93B-11.0%$2.17B-24.5%
Price / earnings29.1×-21.1×50.2×-38.9×89.1×+9.1×79.9×+10.0×69.9×-57.2×
Price / sales4.7×-1.7×6.4×+1.0×5.5×+1.1×4.4×-0.6×-1.9×
Price / book1.9×-0.6×2.5×+0.4×2.1×+0.4×1.7×-0.2×1.9×-0.7×
EV / EBITDA23.6×-14.4×37.9×-13.5×51.4×-1.1×52.6×+6.2×46.3×-26.4×
EV / sales4.3×-1.5×5.8×+0.9×4.9×+0.9×-0.7×4.7×-1.8×
Free cash flow yield6.1%+2.3pp3.8%+0.2pp3.6%-0.4pp4%+0.6pp3.4%+1.3pp
Earnings yield3.4%+1.4pp2%+0.9pp1.1%-0.1pp1.3%-0.2pp1.4%+0.6pp
PEG ratio0.2×-0.1×0.3×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Veracyte's profit margins?
Veracyte (VCYT) runs a 70.9% gross margin and a 14.3% operating margin, with a 16.2% net margin.
Where do Veracyte's ratios come from?
Every ratio is computed from Veracyte's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.